Back

Scarless circular mRNA-based CAR-T cell therapy elicits superior anti-tumor efficacy

Hu, Q.; Zhao, H.; Zhou, K.; Hua, X.; Zhang, X.

2024-08-05 immunology
10.1101/2024.08.05.606578 bioRxiv
Show abstract

Messenger RNA (mRNA)-based transient expression of CAR shows optimal safety profiles and provides promising opportunities to address existing challenges of viral vector-based CAR-T therapies and to meet emerging medical needs in noncancerous indications. However, linear mRNAs are intrinsically unstable and thus just achieve compromised efficacy. Here, we engineered a permuted intron exon (PIE) platform to synthesize scarless circular mRNA (cmRNA) for potent CAR expression and long-lasting efficacy. cmRNA significantly increased amount and duration of anti-CD19 CAR expression on human T cells. cmRNA-based anti-CD19 CAR-T cells elicit superior anti-tumor efficacy over linear mRNA counterparts, demonstrated by parallel lines of evidence including in vitro specific cell-killing, cytokine release, transcriptomics patterns, and in vivo tumor elimination and survival benefit. We found that cmRNA-based anti-CD19 CAR-T efficiently eliminated target cells in vivo and provide long-lasting antitumor efficacy. These results suggested that cmRNA could be a potent platform for unleashing full potential of mRNA technologies in cell therapies.

Matching journals

The top 7 journals account for 50% of the predicted probability mass.

1
Molecular Therapy
○ 81 papers in training set
Top 0.1%
15.1%
Similar papers in this journal
2
Molecular Therapy - Nucleic Acids
○ 25 papers in training set
Top 0.1%
7.9%
Similar papers in this journal
3
Molecular Therapy Nucleic Acids
○ 39 papers in training set
Top 0.1%
7.9%
Similar papers in this journal
4
Nature Communications
○ 5641 papers in training set
Top 26%
5.6%
Similar papers in this journal
5
Advanced Science
○ 286 papers in training set
Top 1%
5.5%
Similar papers in this journal
6
Journal of Controlled Release
○ 44 papers in training set
Top 0.2%
5.2%
7
Biotechnology Journal
○ 11 papers in training set
Top 0.1%
4.3%
50% of probability mass above
8
Molecular Therapy - Methods & Clinical Development
○ 38 papers in training set
Top 0.2%
2.6%
9
eLife
● 5828 papers in training set
Top 40%
2.6%
10
iScience
○ 1154 papers in training set
Top 13%
2.1%
11
Cancer Letters
○ 35 papers in training set
Top 0.4%
2.1%
12
Cell Reports Medicine
○ 153 papers in training set
Top 2%
2.1%
13
Cell Discovery
○ 57 papers in training set
Top 0.4%
1.9%
14
Science Advances
● 1243 papers in training set
Top 19%
1.7%
15
Theranostics
● 37 papers in training set
Top 0.4%
1.7%
16
Molecular Therapy Oncology
○ 10 papers in training set
Top 0.1%
1.3%
17
Scientific Reports
○ 3612 papers in training set
Top 63%
1.1%
18
Small Methods
○ 29 papers in training set
Top 0.4%
1.1%
19
Acta Pharmaceutica Sinica B
○ 11 papers in training set
Top 0.2%
1.1%
20
Frontiers in Immunology
○ 638 papers in training set
Top 7%
1.1%
21
Cancer Immunology Research
● 35 papers in training set
Top 0.7%
1.1%
22
ACS Nano
● 113 papers in training set
Top 2%
1.0%
23
Nucleic Acids Research
◐ 1281 papers in training set
Top 13%
0.8%
24
Communications Biology
○ 993 papers in training set
Top 30%
0.8%
25
Signal Transduction and Targeted Therapy
○ 30 papers in training set
Top 0.6%
0.8%
26
Protein & Cell
◐ 25 papers in training set
Top 0.6%
0.6%
27
Advanced Functional Materials
○ 46 papers in training set
Top 1%
0.6%
28
Cancers
○ 213 papers in training set
Top 5%
0.6%
29
International Immunopharmacology
○ 15 papers in training set
Top 0.4%
0.6%
30
Cell Research
○ 51 papers in training set
Top 2%
0.6%

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.